SUO 2022 Bladder Cancer

REVIEW UroToday

Viewing 1-14 of 14 articles

SUO 2022: Intermediate Risk Non-Muscle Invasive Bladder Cancer: “New” Definitions

SUO 2022: Intermediate Risk: New Trials and Horizons

SUO 2022: Looking Towards the Future: Non-Muscle Invasive Bladder Cancer Trials Reading Out in 24 Months

SUO 2022: Utility of Cxbladder Monitor in Surveillance

SUO 2022: BCG Naïve - FDA: 1 Year from Symposia

SUO 2022: “Remote” Monitoring in Urologic Cancer: The Case for Home Based Testing in Bladder Cancer

SUO 2022: Revisiting Neoadjuvant Therapy Before Prostatectomy

SUO 2022: Addressing Mental Illness and Suicidality in Men With Prostate Cancer

SUO 2022: A Phase 1 Dose-escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer

SUO 2022: A Phase 3 Single-Arm Study of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

SUO 2022: Real Life Impact of Cxbladder Tests on Diagnosis and Surveillance of Bladder Cancer

SUO 2022: Neoadjuvant Chemotherapy and Bladder Sparing Surgery for Muscle Invasive Bladder Cancer: An Old-New De-Escalation Strategy

SUO 2022: The Impact of Blue Light Cystoscopy on Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients Treated in a Real-World Setting

SUO 2022: Real-World Pembrolizumab Utilization Patterns for High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Claims-Based Analysis